Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (331-340 of 755) with videos related to

Pageof 76
Sort By:
Clinical and Experimental Rheumatology|October 5, 2011
Therapeutic approach to familial Mediterranean fever: a review updateMehmet Akif Ozturk, Mehmet Kanbay, Benan Kasapoglu, et al.
BMJ Open|September 28, 2014
Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocolAnna Dossing, Simon Tarp, Daniel E Furst, et al.
Clinical Immunology (Orlando, Fla.)|October 22, 2011
Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosisAnagha A Divekar, Dinesh Khanna, Fereidoun Abtin, et al.
Journal of Scleroderma and Related Disorders|April 6, 2022
Etiology unknown: Qualitative analysis of patient attributions of causality in sclerodermaShadi Gholizadeh, Julia H Drizin, Ingunn Hansdottir, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 2, 2006
Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases--a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic and mesenchymal stem cell therapyLinda M Griffith, Steven Z Pavletic, Alan Tyndall, et al.
JCI Insight|May 4, 2018
pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosisSuzanne Kafaja, Isela Valera, Anagha A Divekar, et al.
Journal of Scleroderma and Related Disorders|June 7, 2023
Factors associated with life satisfaction in systemic sclerosis: Examining the moderating roles of social support and spiritual well-beingYen T Chen, Susan L Murphy, Daniel E Furst, et al.
Plos One|September 12, 2015
Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological StudyAnton Wulf Christensen, Simon Tarp, Daniel E Furst, et al.
Annals of the Rheumatic Diseases|May 1, 1993
Radiological progression in rheumatoid arthritis: how many patients are required in a treatment trial to test disease modification?J T Sharp, F Wolfe, M Corbett, et al.
The Journal of Rheumatology. Supplement|May 1, 1997
Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: paradigm for autoimmune diseaseR A Nash, P A McSweeney, R Storb, et al.
Pageof 76

Showing results (331-340 of 755) with videos related to

Sort By:
Pageof 76
Clinical and Experimental Rheumatology|October 5, 2011
Therapeutic approach to familial Mediterranean fever: a review updateMehmet Akif Ozturk, Mehmet Kanbay, Benan Kasapoglu, et al.
BMJ Open|September 28, 2014
Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocolAnna Dossing, Simon Tarp, Daniel E Furst, et al.
Clinical Immunology (Orlando, Fla.)|October 22, 2011
Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosisAnagha A Divekar, Dinesh Khanna, Fereidoun Abtin, et al.
Journal of Scleroderma and Related Disorders|April 6, 2022
Etiology unknown: Qualitative analysis of patient attributions of causality in sclerodermaShadi Gholizadeh, Julia H Drizin, Ingunn Hansdottir, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 2, 2006
Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases--a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic and mesenchymal stem cell therapyLinda M Griffith, Steven Z Pavletic, Alan Tyndall, et al.
JCI Insight|May 4, 2018
pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosisSuzanne Kafaja, Isela Valera, Anagha A Divekar, et al.
Journal of Scleroderma and Related Disorders|June 7, 2023
Factors associated with life satisfaction in systemic sclerosis: Examining the moderating roles of social support and spiritual well-beingYen T Chen, Susan L Murphy, Daniel E Furst, et al.
Plos One|September 12, 2015
Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological StudyAnton Wulf Christensen, Simon Tarp, Daniel E Furst, et al.
Annals of the Rheumatic Diseases|May 1, 1993
Radiological progression in rheumatoid arthritis: how many patients are required in a treatment trial to test disease modification?J T Sharp, F Wolfe, M Corbett, et al.
The Journal of Rheumatology. Supplement|May 1, 1997
Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: paradigm for autoimmune diseaseR A Nash, P A McSweeney, R Storb, et al.
Pageof 76